A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Armata Pharmaceuticals, Inc.
ARMP
$99M
Mkt Cap
$4.66
-10.73%
Armata Pharmaceuticals, Inc. (ARMP) has a 5-year average return on invested capital (ROIC) of -80.4%. This is below average and may indicate limited pricing power.
Armata Pharmaceuticals, Inc. (ARMP) has a market capitalization of $170M. It is classified as a small-cap stock.
Armata Pharmaceuticals, Inc. (ARMP) does not currently pay a regular dividend.
Armata Pharmaceuticals, Inc. (ARMP) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Armata Pharmaceuticals, Inc. (ARMP) generated $-39 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Armata Pharmaceuticals, Inc. (ARMP) reported earnings per share (EPS) of $-0.89 in its most recent fiscal year.
The Ledger Terminal provides 11 years of financial data for Armata Pharmaceuticals, Inc. (ARMP), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
We are a clinical-stage biotechnology company having completed three Phase 2 trials focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology. We see bacteriophages as a potentially safer and effective alternative to antibiotics and an essential response to the growing bacterial resistance to current classes of antibiotics. Bacteriophages or “phages” have a powerful and highly differentiated mechanism of action that enables binding to and killing of specific targeted bacteria while uniquely preserving the normal human microbiome or “healthy bacteria”. This is in direct contrast to traditional broad-spectrum antibiotics which can alter the human microbiome increasing susceptibility to opportunistic pathogens, such as Clostridium difficile (“C. difficile”).
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 4.9M | - | - | - | - | - |
| Net Income | -174M | -19M | -69M | -37M | -23M | -22M |
| EPS | $-4.78 | $-0.89 | $-1.91 | $-1.08 | $-0.96 | $-1.35 |
| Free Cash Flow | -26M | -39M | -56M | -35M | -25M | -19M |
| ROIC | -37.6% | -49.1% | -41.6% | -102.3% | -91.2% | -117.6% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -1.95 | -1.93 | 1.66 | 1.75 | 1.10 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -37M | -42M | -41M | -37M | -24M | -22M |
| Operating Margin | -747.0% | - | - | - | - | - |
| ROE | 0.0% | - | - | -102.3% | -91.2% | -117.6% |
| Shares Outstanding | 36M | 21M | 36M | 34M | 24M | 16M |
| Metric | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | N/A | N/A | N/A | 260K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 4.9M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 6.5M | 5.8M | 4.0M | 5.7M | 2.9M | 9.8M | 14M | 20M | 35M | 34M | 34M | 24M |
| SG&A | 6.0M | 6.9M | 6.7M | 8.4M | 7.6M | 9.3M | 8.0M | 8.3M | 7.4M | 12M | 13M | 12M |
| EBIT | -12M | -14M | -10M | -23M | -16M | -20M | -22M | -24M | -37M | -41M | -42M | -37M |
| Op. Margin | N/A | N/A | N/A | -8991.5% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -747.0% |
| Net Income | -65M | 16M | -11M | N/A | -13M | -19M | -22M | -23M | -37M | -69M | -19M | -174M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -3544.0% |
| Non-Recurring | 0 | 1.9M | 289K | 9.5M | 5.8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||||||
| ROIC | -30.0% | -49.3% | -84.9% | N/A | -114.6% | -133.5% | -117.6% | -91.2% | -102.3% | -41.6% | -49.1% | -37.6% |
| ROE | N/A | -164.2% | -84.9% | N/A | -166.1% | -133.5% | -117.6% | -91.2% | -102.3% | N/A | N/A | 0.0% |
| ROA | -158.2% | 45.1% | -34.3% | N/A | -115.3% | -76.5% | -56.1% | -33.2% | -38.5% | -70.2% | -20.5% | -226.1% |
| Cash Flow | ||||||||||||
| Op. Cash Flow | -6.3M | 13M | -9.8M | -11M | -9.2M | -16M | -18M | -24M | -32M | -47M | -38M | -26M |
| Free Cash Flow | -6.4M | 11M | -10.0M | -11M | -9.3M | -16M | -19M | -25M | -35M | -56M | -39M | -26M |
| Owner Earnings | -7.8M | 12M | -11M | -13M | -10M | -21M | -23M | -28M | -36M | -49M | -42M | -42M |
| CapEx | 102K | 1.2M | 210K | 279K | 58K | 224K | 824K | 1.3M | 2.2M | 8.1M | 1.9M | 542K |
| Maint. CapEx | 113K | 158K | 330K | 369K | 374K | 1.4M | 1.1M | 1.2M | 892K | 972K | 1.3M | 14M |
| Growth CapEx | 0 | 1.0M | 0 | 0 | 0 | 0 | 0 | 135K | 1.3M | 7.2M | 554K | 0 |
| D&A | 113K | 158K | 330K | 369K | 374K | 1.4M | 1.1M | 1.2M | 892K | 972K | 1.3M | 14M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||||
| Dividends Paid | 0 | 0 | 0 | 80K | 80K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 1.4M | 775K | 483K | 2.0M | 700K | 4.3M | 3.5M | 2.9M | 3.1M | 938K | 2.9M | 2.6M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||||||
| Net Debt | N/A | N/A | N/A | -9.8M | -9.5M | -9.2M | N/A | N/A | N/A | 35M | 75M | 94M |
| Cash & Equiv. | 20M | 6.6M | 9.4M | 5.7M | 5.1M | 6.0M | 9.6M | 10M | 15M | 14M | 9.3M | 8.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 24M | 23M | 103M |
| Debt/Equity | -2.82 | 6.75 | 0.54 | 0.17 | 0.10 | 0.20 | 1.10 | 1.75 | 1.66 | -1.93 | -1.95 | 0.00 |
| Interest Coverage | -53.2 | N/A | N/A | -3896.3 | N/A | -21.2 | -34.4 | -372.2 | N/A | -10.6 | -19.6 | -19.6 |
| Equity | -23M | 3.4M | 13M | 9.7M | 7.7M | 15M | 19M | 25M | 36M | -32M | -48M | -219M |
| Total Assets | 41M | 29M | 31M | 18M | 11M | 25M | 40M | 70M | 96M | 98M | 86M | 77M |
| Total Liabilities | 64M | 23M | 6.9M | 8.4M | 3.4M | 11M | 21M | 44M | 60M | 130M | 134M | 295M |
| Intangibles | 12M | 12M | 12M | 10M | 4.7M | 10M | 10M | 10M | 10M | 10M | 10M | 10M |
| Retained Earnings | -385M | -362M | -363M | -381M | -394M | -158M | -180M | -203M | -240M | -309M | -328M | -502M |
| Working Capital | 18M | 5.2M | 7.6M | 2.8M | 3.4M | 1.8M | 4.1M | 10M | 2.2M | 2.7M | -37M | 1.7M |
| Current Assets | 21M | 7.0M | 10M | 6.3M | 5.4M | 6.7M | 11M | 15M | 27M | 19M | 11M | 11M |
| Current Liabilities | 2.4M | 1.9M | 2.4M | 3.5M | 2.0M | 4.9M | 6.7M | 4.8M | 25M | 16M | 48M | 8.9M |
| Per Share Data | ||||||||||||
| EPS | -23.52 | 145.38 | -278.60 | -3,453.80 | -30.52 | -2.55 | -1.35 | -0.96 | -1.08 | -1.91 | -0.89 | -4.78 |
| Owner EPS | -2.83 | 107.38 | -89.95 | -132.58 | -4.45 | -0.85 | -1.39 | -1.15 | -1.07 | -1.36 | -1.97 | -1.16 |
| Book Value | -8.16 | 31.71 | 107.95 | 99.39 | 3.35 | 0.59 | 1.15 | 1.05 | 1.06 | -0.89 | -2.26 | -6.00 |
| Cash Flow/Share | -2.27 | 115.99 | -83.05 | -108.42 | -3.98 | -0.62 | -1.11 | -0.98 | -0.95 | -1.31 | -1.77 | -4.39 |
| Dividends/Share | N/A | N/A | N/A | 0.82 | 0.03 | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 2.8M | 0.1M | 0.1M | 0.1M | 2.3M | 24.9M | 16.4M | 24.1M | 34.2M | 36.1M | 21.3M | 36.4M |
| Valuation | ||||||||||||
| P/E Ratio | N/A | 2.3 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1.0 |
| P/FCF | N/A | 10.7 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 14.5 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 34.6 |
| FCF Yield | -16.1% | 22.8% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -15.5% |
| Market Cap | 40M | 50M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 170M |
| Avg. Price | 2,245.28 | 2,767.65 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.66 |
| Year-End Price | 2,730.00 | 1,120.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.66 |
Armata Pharmaceuticals, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Armata Pharmaceuticals, Inc. (ARMP) has a book value per share of $-2.26, based on its most recent annual SEC filing.